Lack of evidence of Borrelia involvement in Alzheimer's disease.

formation was published in an erratum in the February issue of the Journal [2]. This is an obvious error, because the study, funded by Merck & Co., used the Merck & Co. product RECOMBIVAX HB/H-B-VaxII. The Discussion section discussed only the use of RECOMBIVAX HB/H-B-VaxII as a 2-dose regimen. It was not our intent to suggest that the Twinrix product did not stimulate a good immunologic response. We regret any confusion that this may have caused for the reader, and we certainly regret the concerns that it has caused for SmithKline Beecham and Merck & Co.